Oculis Holding AG OCS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $11.95
- Day Range
- $12.00–12.04
- 52-Week Range
- $9.05–14.50
- Bid/Ask
- $12.01 / $12.50
- Market Cap
- $500.63 Mil
- Volume/Avg
- 88,399 / 40,492
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 36
- Website
- https://www.oculis.com
Comparables
Valuation
|
Metric
|
OCS
|
VECT
|
MLTX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 4.21 | 4.95 | 5.15 |
Price/Sales | — | 27.19 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
OCS
|
VECT
|
MLTX
|
|---|---|---|---|
Quick Ratio | 4.86 | 9.01 | 51.38 |
Current Ratio | 5.29 | 9.14 | 51.59 |
Interest Coverage | −67.54 | −41.28 | — |
Quick Ratio
OCS
VECT
MLTX
Profitability
|
Metric
|
OCS
|
VECT
|
MLTX
|
|---|---|---|---|
Return on Assets (Normalized) | −48.64% | −37.23% | −11.20% |
Return on Equity (Normalized) | −101.02% | −44.82% | −12.51% |
Return on Invested Capital (Normalized) | −91.50% | −42.88% | −11.49% |
Return on Assets
OCS
VECT
MLTX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Dzcmvwxgw | Rfxg | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Ddplvfff | Mrcxc | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Kkjpchzn | Cjrtw | $97.8 Bil | |
MRNA
| Moderna Inc | Wjdzjdr | Zgx | $41.3 Bil | |
ARGX
| argenx SE ADR | Djykxqmd | Kzqk | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Qhcvbbkr | Mmhyc | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Hjngzgjfk | Lgcfcd | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Srgvjbyy | Qvwhcn | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Gjbqjxbbt | Qwkcsr | $12.5 Bil | |
INCY
| Incyte Corp | Glptyllf | Hwkrmlh | $11.6 Bil |